News for 'Cadila Pharmaceuticals Ltd'

'Sword to kill mosquito': HC raps Maha FDA over Cadila drug action

'Sword to kill mosquito': HC raps Maha FDA over Cadila drug action

Rediff.com11 Aug 2026

The Bombay High Court has strongly criticised the Maharashtra FDA for its "shoot first" approach, likening its drastic actions to using a sword to kill a mosquito. The court, hearing a petition from Cadila Pharmaceuticals, directed the FDA to grant companies a hearing before taking severe measures, warning of heavy costs for its arbitrary conduct.

Cadila to market anti-cancer drug by 2006

Cadila to market anti-cancer drug by 2006

Rediff.com14 Nov 2005

Cadila Pharmaceuticals Ltd on Monday said it would market anti-cancer drugs GCS

Pharma co's Gujarat SEZ plan runs into hurdle

Pharma co's Gujarat SEZ plan runs into hurdle

Rediff.com12 Oct 2009

A Union environment ministry's expert appraisal panel felt that the project proponent, CPL Infrastructure Pvt Ltd, a subsidiary of Cadila Pharmaceuticals Ltd, had failed to give requisite details for the proposed park in Dhandhuka Taluka in Ahmedabad.

Cadila drug gets USFDA nod

Cadila drug gets USFDA nod

Rediff.com1 Jun 2006

Cadila Healthcare Ltd has received approval from USFDA for marketing anti-coagulant, Warfarin tablets.

Cadila gets USFDA nod for Gatifloxacin

Cadila gets USFDA nod for Gatifloxacin

Rediff.com29 Nov 2005

Cadila Healthcare Ltd has received tentative approval from US FDA to market its antibiotic, Gatifloxacin tablets, 200 mg and 400 mg, in the US market.

Zydus Cadila to sell Atenolol in US

Zydus Cadila to sell Atenolol in US

Rediff.com1 Feb 2005

Cadila Healthcare Ltd has announced that Zydus Cadila has received its very first approval from USFDA to market Atenolol, an anti-hypertensive drug, in the US market.

Cadila gets tentative FDA nod

Cadila gets tentative FDA nod

Rediff.com15 Jun 2006

Cadila Healthcare Ltd has received tentative approval from the USFDA to market Pravastatin Sodium Tablets in the US market.

Cadila gets USFDA approval for Levofloxacin

Cadila gets USFDA approval for Levofloxacin

Rediff.com24 Apr 2006

Cadila Healthcare Ltd on Monday said it has received tentative approval from the US FDA to market Levofloxacin tablets of 250 mg, 500 mg and 750 mg in the US market.

Gujarat pharma hub hit by near-zero exports

Gujarat pharma hub hit by near-zero exports

Rediff.com15 Apr 2020

With the government asking the companies to operate with only 50 per cent staff strength, and exports dipping to almost zero, the truck and bus drivers idling at the petrol pump say they hardly have any work now. At a petrol pump on the deserted Bavla-Changodar highway near Ahmedabad in Gujarat, several trucks and buses are neatly parked in a row.

ASK AJIT: 'Which shares to buy short term and long term?'

ASK AJIT: 'Which shares to buy short term and long term?'

Rediff.com17 Jan 2022

Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.

PM holds meet with teams involved in developing COVID vaccine

PM holds meet with teams involved in developing COVID vaccine

Rediff.com30 Nov 2020

The teams were from Gennova Biopharmaceuticals Ltd Pune, Biological E Ltd Hyderabad and Dr Reddys Laboratories Ltd Hyderabad.

Prices of 52 more 'essential' drugs capped

Prices of 52 more 'essential' drugs capped

Rediff.com12 Dec 2014

The new drugs to come under price control include commonly-used antibiotics and painkillers

Diabetes medicines, antibiotics to now get cheaper in India

Diabetes medicines, antibiotics to now get cheaper in India

Rediff.com16 Jul 2015

Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.

36 drugs to be cheaper as govt caps prices

36 drugs to be cheaper as govt caps prices

Rediff.com19 Sep 2014

India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority told Reuters on Friday.

Is my portfolio good?'

Is my portfolio good?'

Rediff.com31 Jan 2022

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

ASK AJIT: 'How can I make money?'

ASK AJIT: 'How can I make money?'

Rediff.com24 Feb 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.

Zydus unveils 43 generics in France

Zydus unveils 43 generics in France

Rediff.com17 Sep 2004

First-time investor: 'I can afford only low-price stocks'

First-time investor: 'I can afford only low-price stocks'

Rediff.com12 Jan 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Pfizer seeks approval in India for Covid vaccine

Pfizer seeks approval in India for Covid vaccine

Rediff.com6 Dec 2020

'Pfizer India has submitted an application on December 4 to the DCGI seeking emergency use authorization for its COVID-19 vaccine in India'

3 COVID vaccines under active consideration: Health ministry

3 COVID vaccines under active consideration: Health ministry

Rediff.com8 Dec 2020

Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India seeking emergency use authorisation for their COVID-19 vaccines.

'Dear Ajit: Need your advice on mid- and small-caps'

'Dear Ajit: Need your advice on mid- and small-caps'

Rediff.com30 Jul 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

ASK AJIT: How to get 20% return on shares?

ASK AJIT: How to get 20% return on shares?

Rediff.com17 Dec 2021

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

How long before the world gets a COVID-19 vaccine?

How long before the world gets a COVID-19 vaccine?

Rediff.com28 Apr 2020

More than 2 million people have been diagnosed with coronavirus across the world, and the pharmaceutical industry is pulling out all stops to find potential treatments and vaccines for the global pandemic. According to the World Health Organization, there are now more than 70 potential vaccines under evelopment, with some already in clinical trials.

Stocks you must buy, hold or exit

Stocks you must buy, hold or exit

Rediff.com25 Aug 2020

Ajit Mishra, vice president, Research, Religare Broking, answers your queries:

Drugmakers draw more FDA scrutiny as US imports rise

Drugmakers draw more FDA scrutiny as US imports rise

Rediff.com13 Sep 2013

And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.

Myanmar allows traffic rights to Indian airlines

Myanmar allows traffic rights to Indian airlines

Rediff.com10 Jun 2013

At present, there is no direct air connectivity between India and Myanmar.

'Hold or exit from these stocks?'

'Hold or exit from these stocks?'

Rediff.com22 Oct 2020

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

24 SEZ developers seek more time for projects

24 SEZ developers seek more time for projects

Rediff.com16 Jan 2014

As many as 24 special economic zone (SEZ) developers including Dr Reddy's Lab and Tata Consultancy Services have sought more time from the government to execute their projects.

India, China sign business deals worth $3.4 billion

India, China sign business deals worth $3.4 billion

Rediff.com18 Sep 2014

IndiGo Airlines signs $2.6-billion leasing and financing MoU with Industrial and Commercial Bank of China.

Pharma in 2014: Deals worth billions and fines worth millions

Pharma in 2014: Deals worth billions and fines worth millions

Rediff.com26 Dec 2014

In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.

Stock advice: Readers' queries answered!

Stock advice: Readers' queries answered!

Rediff.com14 Aug 2019

Ajit Mishra, Vice President, Research, Religare Broking, answers readers' stock market queries. Ajit will offer his unbiased views on a weekly basis